Skip to main content
Staff Login
Username
*
Enter your The Contraceptive Pipeline Database username.
Password
*
Enter the password that accompanies your username.
Log in
Forgot password
Toggle navigation
ellaOne
Product Overview
Development Status:
SRA/WHO PQ Approved
Target:
Female
Mode:
Hormonal
Delivery Type:
Oral
Duration Type:
Emergency
Description:
Emergency contraceptive pill with ulipristal acetate (UPA).
Updated date:
May 30, 2018
Vertical Tabs
Product Details
Active Pharmaceutical Ingredient (API):
ulipristal acetate
Potential Multi-Purpose Technology (MPT):
No
Regimen:
Single tablet taken up to 5 days after unprotected intercourse
Duration:
single act
Dose:
30 mg
Partner:
HRA Pharma
Status
Project Phase:
Post-development
Project Stage:
Marketed
Status Details:
ellaOne was approved in 2009 throughout the European Union by the European Medicines Agency (EMA) and by the FDA in 2010. It is marketed in over 60 countries.
Programmatic Considerations
Considerations:
Clinical data shows that UPA is at least as effective as current LNG emergency contraception and offers better efficacy than LNG to women who come late for EC (days 3 to 5 post-coital).
ellaOne costs approximately three times more than currently available oral emergency contraception options.
Additional Information
Additional Information:
HRA Pharma website
Download Product Report
